Enclomiphene and clomiphene are closely related medicines that can affect the body’s hormone signaling system. They are often discussed in connection with low testosterone, male fertility, and hypogonadism. Although the names sound similar, they are not exactly the same product. Clomiphene is a mixture of two isomers, while enclomiphene is one of those isomers. This difference has led researchers to study whether enclomiphene can provide some of the hormonal effects of clomiphene with a different side-effect profile.
The comparison becomes especially important for men with secondary hypogonadism who want to increase testosterone while maintaining sperm production. Research has found that selective estrogen receptor modulators, including clomiphene and enclomiphene, can raise testosterone and gonadotropin levels in selected men. However, the evidence is still developing, and these medicines should not be treated as interchangeable without medical guidance.
What Is Clomiphene?
Clomiphene, also called clomiphene citrate, is a selective estrogen receptor modulator, or SERM. It has been used for decades, with its established U.S. labeling focused on inducing ovulation in women with ovulatory dysfunction. The medicine works by interacting with estrogen receptors and altering feedback signals between the brain and reproductive system. This can increase the release of hormones involved in reproductive function.
Clomiphene is also used by some clinicians off-label in men with certain forms of hypogonadism or fertility problems. In men, the goal is generally different from its labeled use in women. Instead of directly supplying testosterone, clomiphene can stimulate the body’s own hormonal pathway, potentially increasing luteinizing hormone, follicle-stimulating hormone, and testosterone. Research has reported increases in testosterone with clomiphene treatment, although individual responses vary.
What Is Enclomiphene?
Enclomiphene is the trans-isomer of clomiphene citrate. In simple terms, clomiphene contains two related forms, known as enclomiphene and zuclomiphene. FDA briefing materials describe clomiphene as containing approximately 62% enclomiphene and 38% zuclomiphene. The two isomers have different pharmacological properties, which is one reason researchers have investigated enclomiphene separately.
Enclomiphene has been studied particularly in men with secondary hypogonadism. Clinical research has shown that it can increase testosterone while also increasing hormones such as LH and FSH. In a randomized phase II trial, enclomiphene increased morning testosterone and preserved sperm production compared with topical testosterone therapy. These findings made it an area of interest for men whose fertility is an important consideration.
Enclomiphene vs Clomiphene: The Main Difference
The most basic difference is chemical composition. Clomiphene citrate is a mixture containing two stereoisomers, whereas enclomiphene represents the trans-isomer on its own. Zuclomiphene has different estrogen-receptor activity and a longer reported half-life than enclomiphene. Because of these differences, researchers have explored whether using enclomiphene alone may produce a more targeted hormonal effect.
This distinction does not mean that enclomiphene is automatically better than clomiphene. Clinical outcomes depend on the underlying condition, the patient’s hormone levels, fertility goals, other health factors, and the treatment approach. A 2025 systematic review and meta-analysis found that SERM therapy, including clomiphene and enclomiphene, was associated with improvements in total testosterone, LH, and FSH in men with functional hypogonadism.
How Do They Affect Testosterone?
Both medicines can influence the hormonal feedback system that controls testosterone production. Rather than replacing testosterone from outside the body, SERMs can reduce estrogen’s feedback signal at certain receptors in the hypothalamus and pituitary. This can encourage the release of LH and FSH, which then stimulate the testes. The resulting increase in testosterone is therefore produced through the body’s own reproductive hormone pathway.
Clinical studies support this general effect. Research involving enclomiphene has shown increased testosterone together with increases in LH and FSH, while studies of clomiphene have also reported higher testosterone levels in men with hypogonadism. A recent meta-analysis found that SERM treatment significantly increased total testosterone compared with placebo, although the studies differed substantially in design and patient populations.
What About Male Fertility?
Fertility is one of the main reasons the difference between testosterone replacement and SERMs receives attention. External testosterone can suppress the body’s own reproductive hormone signals and, as a result, reduce sperm production. SERMs work through a different pathway and may allow testosterone to rise while maintaining gonadotropin signaling.
Enclomiphene has specifically been studied for this reason. A randomized phase II trial reported that men receiving enclomiphene maintained sperm production while increasing testosterone and gonadotropin levels. A retrospective study comparing enclomiphene and clomiphene also found increases in testosterone with both treatments and reported improvements in some sperm-related measures with enclomiphene. However, that study was retrospective, so its results cannot establish that enclomiphene is superior.
Are Their Side Effects Different?
Side effects can occur with both medicines, and the available evidence does not justify assuming that one option is universally safer. Clomiphene’s prescribing information includes warnings about visual symptoms, which can occasionally be prolonged or, in rare cases, irreversible. The label also contains important warnings and contraindications related to its approved use for ovulation induction.
Some research suggests that enclomiphene may produce fewer adverse effects than clomiphene in certain men, but the evidence remains limited. A 2024 retrospective study involving 66 patients found a lower rate of documented adverse events during enclomiphene treatment and a smaller change in estradiol compared with clomiphene. However, the study was not a large randomized clinical trial, and the authors called for further research to confirm the findings.
Is Enclomiphene FDA Approved?
This is an important distinction when comparing the two medicines. Clomiphene citrate has an established FDA-approved indication for ovulatory dysfunction in appropriately selected women. Its use in men for hypogonadism is generally considered off-label.
Enclomiphene has been investigated for male hypogonadism, but it should not be described as an FDA-approved treatment for low testosterone simply because clinical trials have studied it. An FDA briefing document discussed enclomiphene as a potential treatment for secondary hypogonadism and noted that FDA-approved testosterone products and other therapies were available. Current clinical literature continues to describe enclomiphene as an investigational or non-approved option in this setting.
Enclomiphene vs Clomiphene for Low Testosterone
For men with low testosterone caused by secondary hypogonadism, both drugs have been investigated because they can stimulate endogenous testosterone production. Research does not support a simple conclusion that one medicine works better for every patient. A 2025 systematic review found that SERM therapy improved testosterone, LH, and FSH compared with placebo, but the studies included different treatments and patient groups.
Individual treatment decisions therefore depend on why testosterone is low. A physician may consider hormone measurements, symptoms, fertility plans, age, underlying medical conditions, medications, and other laboratory findings. Treating a laboratory number alone may not address the actual cause of low testosterone. Proper evaluation is especially important because hypogonadism can have several different causes.
Enclomiphene vs Clomiphene for Fertility
| Feature | Enclomiphene | Clomiphene |
|---|---|---|
| Drug class | Selective estrogen receptor modulator (SERM) | Selective estrogen receptor modulator (SERM) |
| Relationship | One isomer of clomiphene | Mixture of enclomiphene and zuclomiphene |
| Main research interest | Male hypogonadism and testosterone restoration | Ovulation induction and off-label male hormone treatment |
| Testosterone effect in studied men | Can increase testosterone | Can increase testosterone |
| LH/FSH effect | Can increase LH and FSH | Can increase LH and FSH |
| Fertility interest | Studied for maintaining sperm production | Used off-label in some male fertility settings |
| FDA-approved male hypogonadism treatment | No | No |
| FDA-approved use | No FDA-approved indication for male hypogonadism | Ovulatory dysfunction in appropriately selected women |
| Research status | Ongoing clinical research | Long-established clinical use |
| Medical supervision | Recommended | Recommended |
For men who want to preserve fertility, the hormonal mechanism is particularly relevant. Because SERMs stimulate the body’s reproductive hormone pathway rather than directly replacing testosterone, they may be considered in selected situations where maintaining sperm production matters. This is different from conventional testosterone replacement, which can suppress the signals needed for sperm production.
Evidence comparing enclomiphene directly with clomiphene is still limited. One retrospective study of men treated for infertility, abnormal semen parameters, or hypogonadism found that both groups experienced higher total testosterone. The enclomiphene group also showed statistically significant increases in LH and FSH and an increase in total motile sperm count. However, the study was not randomized, so the results should be interpreted cautiously.
What Does Recent Research Say?
Research published through 2025 and 2026 continues to examine SERMs as potential options for selected men with hypogonadism. A 2025 systematic review and meta-analysis found that SERM therapy significantly improved total testosterone, LH, and FSH compared with placebo. It also found no significant difference in total testosterone between SERM therapy and testosterone gel in the analyzed studies.
At the same time, researchers continue to point out limitations in the evidence. Studies vary in size, duration, patient selection, and treatment protocols. A 2026 British Society of Sexual Medicine position statement specifically addressed the potential use of enclomiphene for male hypogonadism, reflecting continued professional interest while the evidence base develops. Long-term data remain important when considering both effectiveness and safety.
Which One Should You Take?
There is no universally appropriate answer to the question of whether enclomiphene or clomiphene should be used. The appropriate choice depends on the medical condition being treated and the goals of treatment. For example, a man being evaluated for secondary hypogonadism and fertility concerns may have different treatment considerations from a woman receiving clomiphene for ovulation induction.
Neither medicine should be started, stopped, or switched without discussing it with a qualified healthcare professional. This is particularly important because formulations, regulatory status, dosing practices, and monitoring requirements can differ. A doctor may also need to investigate the cause of abnormal testosterone levels before deciding whether a SERM is appropriate.
Safety and Medical Monitoring
Medical supervision matters because hormone-modifying medicines can affect several body systems. Clomiphene’s official labeling includes important warnings about visual disturbances and other adverse reactions. Anyone taking clomiphene who develops new visual symptoms should promptly contact their healthcare professional and follow the prescribing information.
Men using SERMs for hypogonadism may require follow-up laboratory testing to assess testosterone and other reproductive hormones. Depending on the situation, clinicians may also monitor symptoms, blood counts, liver function, estradiol, and semen parameters. The exact monitoring plan varies by patient and treatment. Online dosing advice should not replace individualized medical care.
Conclusion
Enclomiphene and clomiphene are closely related SERMs, but they are not identical. Clomiphene is a mixture of enclomiphene and zuclomiphene, while enclomiphene is one specific isomer. Both have been studied for their ability to influence reproductive hormone signaling and increase testosterone in selected men. Research also suggests that SERMs may help maintain aspects of reproductive function that can be suppressed by external testosterone therapy.
The evidence does not establish a universal winner between enclomiphene and clomiphene. Enclomiphene remains an area of ongoing research, while clomiphene has a much longer clinical history and an FDA-approved indication for ovulatory dysfunction in women. For men, both may be used in selected circumstances under medical supervision. Anyone considering either medicine should discuss the potential benefits, risks, fertility goals, and available alternatives with a qualified healthcare professional.
Frequently Asked Questions
What is the main difference between enclomiphene and clomiphene?
Clomiphene contains two isomers, while enclomiphene is the isolated trans-isomer.
Can enclomiphene increase testosterone?
Clinical studies have found that enclomiphene can increase testosterone in selected men with secondary hypogonadism.
Does clomiphene increase testosterone in men?
Studies have reported increased testosterone in some men treated with clomiphene for hypogonadism.
Is enclomiphene FDA approved for low testosterone?
Enclomiphene is not an FDA-approved treatment for male low testosterone.
Is clomiphene FDA approved?
Clomiphene has an FDA-approved indication for ovulatory dysfunction in appropriately selected women.
Can enclomiphene preserve sperm production?
Clinical research has found that enclomiphene can increase testosterone while maintaining sperm production in studied men.
Can clomiphene affect sperm production?
Clomiphene can stimulate the reproductive hormone pathway and has been used off-label in men with fertility concerns.
Which has fewer side effects?
Some observational research has reported fewer adverse events with enclomiphene, but larger studies are needed to confirm this finding.
Can you take enclomiphene and clomiphene together?
They should not be combined unless specifically directed and monitored by a qualified healthcare professional.
Should you switch from clomiphene to enclomiphene?
A medication switch should be discussed with a healthcare professional who can assess the reason for treatment and your response to therapy.
More Update FEATURE POSTS
